Semaglutide's weight effect holds up in Asian adults, pooled trials find

Overweight and obesity are rising sharply across Asian populations, which the authors frame as a critical public health concern. Semaglutide 2.4 mg, a GLP-1 receptor agonist, has already shown substantial weight reduction in global trial programmes, but those programmes were dominated by other populations. Whether the same magnitude of benefit and the same tolerability profile appear in Asian adults had not been examined comprehensively. Pooling the trials that did recruit these populations is the obvious next step before clinicians and readers assume the headline numbers transfer unchanged.

The authors ran a systematic review with meta-analysis and meta-regression, searching Medline, ScienceDirect, Europe PubMed Central and the Cochrane Library up to 15 June 2025. Eligible studies were randomised controlled trials comparing once-weekly subcutaneous semaglutide 2.4 mg with placebo in Asian adults with overweight or obesity. Risk of bias was assessed with the Cochrane Risk of Bias v2 tool, and pooled mean differences and odds ratios were estimated with random-effects models, with heterogeneity quantified by the I2 statistic. Five RCTs involving 2614 participants met the criteria, and all were judged low risk of bias.

The primary weight outcome favoured semaglutide clearly: body weight fell by 8.20% more than with placebo (95% CI -10.06 to -6.35), though heterogeneity was high at I2 = 84%. Secondary measures moved in the same direction, with waist circumference down 6.47 cm, BMI down 3.22 kg/m2 and systolic blood pressure down 3.46 mmHg, the last with much lower heterogeneity (I2 = 28%). More participants on semaglutide crossed the 5%, 10% and 15% weight-loss thresholds than on placebo. Gastrointestinal symptoms were the most frequently reported adverse effects and were generally mild to moderate and self-limiting.

This confirms, rather than overturns, what the global trial programme suggested, and extends it to a population that had been under-represented in the pooled evidence. The consistency of the blood pressure effect across trials is notable given how variable the weight estimates were. Open questions the authors name include long-term effects beyond the trial durations, how well results translate to real-world use outside trial support, and variability between subpopulations within the broad category of 'Asian adults'. Head-to-head comparisons with other agents are also absent from this analysis.

For a reader following the GLP-1 story, this is a reason to think the weight and cardiometabolic effects reported in large international trials are not an artefact of who was recruited. The pooled figures also make clear that the benefit is not weight alone: waist circumference and systolic blood pressure shifted as well. The wide confidence interval and high heterogeneity mean individual results in trials varied considerably, so a single pooled percentage is an average, not a promise. Tolerability in these trials was dominated by digestive symptoms rather than anything more serious.